{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/alopecia-androgenetic-female/management/management/","result":{"pageContext":{"chapter":{"id":"84a05021-8d2e-500f-bac8-1152758fd81c","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 632919a6-8fc9-4e35-9ba2-a4b7bb3267f4 --><h2>Scenario: Management of a woman with androgenetic alopecia</h2><!-- end field 632919a6-8fc9-4e35-9ba2-a4b7bb3267f4 -->","summary":"Covers the management of women with androgenetic alopecia.","htmlStringContent":"<!-- begin item aef2d06e-3c70-4ed0-bb21-3998e82c7dac --><!-- begin field 2b63d6c9-468d-4105-b927-acbc0156bdb6 --><p>From age 18 years onwards (Female).</p><!-- end field 2b63d6c9-468d-4105-b927-acbc0156bdb6 --><!-- end item aef2d06e-3c70-4ed0-bb21-3998e82c7dac -->","topic":{"id":"34cafa57-9383-5d80-b924-585fddfaf630","topicId":"ee168cae-489c-42c8-b09e-953c3911c90a","topicName":"Alopecia, androgenetic - female","slug":"alopecia-androgenetic-female","lastRevised":"Last revised in May 2016","chapters":[{"id":"ed7eb17b-bb56-55c8-93ed-c69fffb8ffb2","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"50eed0df-a1f0-5171-9181-43ae31f74c24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a335b9ba-ae97-56fc-8f3c-67269d2cebee","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"423c1f05-2850-5fc3-9dfe-32260c543c30","slug":"changes","fullItemName":"Changes"},{"id":"98782d6b-86e0-52c6-874d-d38c3a7b8b43","slug":"update","fullItemName":"Update"}]},{"id":"c3b76113-c0a5-51d2-9626-e50262eb0b51","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"26174a6e-62fc-5925-bdc7-6dec1e3cc672","slug":"goals","fullItemName":"Goals"},{"id":"268ede25-aeb2-59d0-8650-e83fb2b7237c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0de2e8e-6151-5970-b442-dab292556f28","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"beac34dd-51e9-51be-b40d-b68c2f22bab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7238b814-3ad5-52e6-ad73-5c5e25e26035","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16239c30-d709-5fbe-b215-e9181602c63f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3e8ded1e-bf8c-5ab8-bae3-0a3718045265","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a41bf35-6b01-5146-9673-3480759cf2b2","slug":"definition","fullItemName":"Definition"},{"id":"3f9115db-2801-58d5-8b38-614632cc8518","slug":"causes","fullItemName":"Causes"},{"id":"22dc1f21-64e2-59d3-9248-27696a2ff2f3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d994014c-2572-5645-8d46-23c950e5e12f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b2055ae4-a6c4-5ea6-8abb-2ada0bfe997f","slug":"complications","fullItemName":"Complications"},{"id":"f6b263b5-2a9d-5889-b83a-31313b2349ba","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c98a08a0-1460-5525-b53e-e7dd062f5271","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d05f7dc4-15b4-51a7-9040-1f13534d2bcd","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"5c4491cc-a38e-5798-9ea5-303e2514c88a","slug":"investigations","fullItemName":"Investigations"},{"id":"8ec69667-1bf4-5d04-8c65-48f0cca236b3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dcc3e89f-77d3-55b8-96a0-7f18236d81ed","fullItemName":"Management","slug":"management","subChapters":[{"id":"84a05021-8d2e-500f-bac8-1152758fd81c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d947b9be-2aca-5db0-bde3-bd1288f9fe15","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52c6980c-f25c-5733-a13e-000bf03bd936","slug":"topical-minoxidil-2percent-solution","fullItemName":"Topical minoxidil 2% solution"}]},{"id":"1f4c5c98-e1a3-5353-af89-7c80d4173e69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a13caaee-1053-53e3-9663-af5cdb6967c3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c996db3c-f9be-5ca7-8fbf-6d8cc2a1dccf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"66cae4ab-b2ad-5800-b305-3061debc9954","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4f39a0f4-1a5f-51fa-ad3f-0bc3472e20ae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebbfb681-3de5-545e-9479-c10e9c16eac3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb1f7555-0114-5914-8728-1ba58437da39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2ef85d5b-cf19-51e6-b768-e1dfbdc625a0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"dcc3e89f-77d3-55b8-96a0-7f18236d81ed","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"deaab677-f2e1-5263-bb4b-e567414a3130","slug":"management-in-primary-care","fullItemName":"Management in primary care","depth":3,"htmlHeader":"<!-- begin field 0531748d-256d-48fa-bd67-cfec35d3c17d --><h3>How should I manage a woman with androgenetic alopecia?</h3><!-- end field 0531748d-256d-48fa-bd67-cfec35d3c17d -->","summary":null,"htmlStringContent":"<!-- begin item 50312f31-0289-4344-a33a-370ff4fe4b99 --><!-- begin field 95968998-c069-4330-8bc9-918f812961bf --><ul><li><strong>Explain the natural course of the condition, what the woman may expect in terms of continuing hair thinning, and long term <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/background-information/prognosis/\">prognosis</a>.</strong><ul><li>Address the fear of going bald which may be unspoken and reassure the woman that:<ul><li>Androgenetic alopecia rarely results in areas of total hair loss in women. Wording such as 'hair loss' and 'thinning' is preferable.</li><li>Hair may be shampooed as frequently as desired without fear of worsening hair loss.</li></ul></li></ul></li><li><strong>Discuss the treatment and <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/management/management/#aesthetic-options\">aesthetic options</a></strong><strong> that are available.</strong><ul><li><strong>No treatment</strong> is an option in mild pattern hair loss. <ul><li>Most women prefer a treatment at some stage, although the use of aesthetic options may be a suitable alternative. </li></ul></li><li><strong>If the woman prefers treatment,</strong> <strong>consider topical minoxidil 2% solution </strong>— this is the only medication licensed for use in female androgenetic alopecia. Discuss with the woman that:<ul><li>It is not prescribable on the NHS but can be bought over-the-counter or prescribed privately for women aged 18-65 years.</li><li>Although it may improve hair regrowth, it is not guaranteed as response varies from person to person. </li><li>To gain and maintain benefit, 1 mL of solution should be applied to the affected areas twice a day, and continued indefinitely.</li><li>The women who respond best are those who have androgenetic alopecia of recent onset or small areas of hair loss.</li><li>About 1 in 4 women report 'moderate' or more hair regrowth.</li><li>Hair regrowth may not be noticed for 3-6 months.</li><li>Stopping treatment will lead to loss of all results within 6-12 months, and the rebound shedding may be severe.</li></ul></li><li><strong>If topical minoxidil is used, assess the response to treatment at 6 months. </strong><ul><li>If successful, continue treatment indefinitely. </li><li>If there is no response after 1 year, discontinue treatment and consider <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/management/management/#referral\">referral</a> to a dermatologist, depending on clinical judgement and the woman's wishes.</li></ul></li><li><strong>Do not offer other drug treatments</strong> such as finasteride or anti-androgens (such as spironolactone or cyproterone) in primary care.</li></ul></li><li><strong>Discuss the use of hairstyling, colouring, and hairsprays to improve the cosmetic appearance.</strong></li><li><strong>Manage any <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/background-information/complications/\">psychological complications</a> appropriately.</strong><ul><li>Local support groups or counselling may be helpful if the woman requires psychological support, such as Alopecia UK (<a href=\"http://www.alopeciaonline.org.uk/\" style=\"background-color: rgb(255, 255, 255);\" data-hyperlink-id=\"225c84f0-940c-44aa-8784-a98f0012b3c9\">www.alopeciaonline.org.uk</a>).</li></ul></li><li>For further information, offer the patient information leaflet <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=3830&itemtype=document\" data-hyperlink-id=\"172773c5-c3cc-4f06-89b0-a98f0012b416\">Female Pattern Hair Loss (Androgenetic Alopecia)</a> which can be found on the British Association of Dermatologists (BAD) website, available at <a href=\"http://www.bad.org.uk/\" data-hyperlink-id=\"7e6bdc5c-b061-4afc-aa9f-a98f0012b42d\">www.bad.org.uk</a>.</li></ul><!-- end field 95968998-c069-4330-8bc9-918f812961bf --><!-- end item 50312f31-0289-4344-a33a-370ff4fe4b99 -->","subChapters":[{"id":"2938fef0-9d0c-530b-8ec0-bbc800bb4ce6","slug":"aesthetic-options","fullItemName":"Aesthetic options","depth":4,"htmlHeader":"<!-- begin field d44edff8-287a-495c-9357-f0885f19d492 --><h4>Aesthetic options</h4><!-- end field d44edff8-287a-495c-9357-f0885f19d492 -->","summary":null,"htmlStringContent":"<!-- begin item 3ea5fa64-b2d9-4a2d-8e4a-77f68b814549 --><!-- begin field abc40759-e131-45ea-80ee-f45bc4c8802f --><ul><li><strong>Hairpieces and wigs </strong>— can be interwoven (these are more expensive and need regular readjustment) or worn on top of the woman's own hair. In certain circumstances, women may be eligible for free or reduced cost wigs on the NHS if an independent funding request is accepted.<ul><li>Be aware that in order to obtain an NHS prescription for a wig, referral to a dermatologist may be required. More information on buying wigs and NHS policy is available at <a href=\"http://www.nhs.uk/NHSEngland/Healthcosts/Pages/Wigsandfabricsupports.aspx\" style=\"background-color: rgb(255, 255, 255);\" target=\"_blank\" data-hyperlink-id=\"66f7b05e-0dc0-46de-8d72-a99300a2a080\">www.nhs.uk/NHSEngland/Healthcosts/Pages/Wigsandfabricsupports.</a></li><li>Further information about synthetic wigs and human hair wigs, including advice about choosing the right wig and how to care for it, is available on the Alopecia UK website at <a href=\"http://authoringtool-jsclient.clarity.co.uk/www.alopeciaonline.org.uk\" style=\"background-color: rgb(255, 255, 255);\" data-hyperlink-id=\"af229518-1876-4789-87a1-a99300a2a1b3\">www.alopeciaonline.org.uk</a>.</li></ul></li><li><strong>Cosmetic options </strong>to camouflage hair loss are not prescribable on the NHS. They include:<ul><li>Hairstyling — waving, dyeing, sprays, and mousses.</li><li>Hair camouflage — such as a keratin microfibre product which may provide scalp cover.</li><li>Hair extensions — provide fullness but may result in further pulling and traction on existing follicles.</li></ul></li><li><strong>Surgical hair transplantation </strong>for androgenetic alopecia is not available on the NHS and the cost to the woman may be prohibitive. <ul><li>Usually only considered for those women with no response to less invasive treatment.</li><li>Modern techniques use follicular unit transplantation to produce a more natural appearance than older techniques such as punch grafts, micro-grafts, slit grafts, and strip grafts. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blumeyer et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Levy and Emer, 2013</a>]</p><!-- end field abc40759-e131-45ea-80ee-f45bc4c8802f --><!-- end item 3ea5fa64-b2d9-4a2d-8e4a-77f68b814549 -->","subChapters":[]},{"id":"04236e59-4a5e-5ad5-b452-ac20b0951f96","slug":"basis-for-recommendation-a83","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9053091b-733c-4d06-a5df-3b0b2c9f5be4 --><h4>Basis for recommendation</h4><!-- end field 9053091b-733c-4d06-a5df-3b0b2c9f5be4 -->","summary":null,"htmlStringContent":"<!-- begin item a83a108b-9b56-4fb3-834a-e4b136dcbc85 --><!-- begin field a9a51014-e38f-4806-8f50-aaf9fd9e1be3 --><p>The recommendations on the management of androgenetic alopecia in women are based on expert opinion in a European consensus guideline for the treatment of androgenetic alopecia in women and men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blumeyer et al, 2011</a>], a Cochrane systematic review of interventions for female pattern hair loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">van Zuuren et al, 2012</a>], expert opinion in review articles on the management of androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Dawber and Rundegren, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Thiedke, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Mapar and Omidian, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Mirmirani, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Avram and Rogers, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Herskovitz et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Levy and Emer, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Torres et al, 2015</a>], the British Medical Journal Best practice article for androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BMJ, 2015</a>], and information in the British National Formularly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BNF 71, 2016</a>] and the manufacturer's Summary of Product Characteristics (SPC) for minoxidil 2% solution [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2015</a>].</p><h5><strong>Topical minoxidil 2% solution</strong></h5><ul><li>Topical minoxidil is only recommended for people aged 18-65 years, as safety and effectiveness outside of this age range has not been established [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2015</a>].</li><li>There is moderate evidence from a Cochrane systematic review that topical minoxidil 2% is of some benefit in the treatment of women with androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">van Zuuren et al, 2012</a>].<ul><li>Pooled data from four RCTs (n = 488) indicated that a greater proportion of participants (121/488) treated with topical minoxidil 2% solution reported a moderate increase in their hair regrowth when compared with placebo (64/476) (risk ratio [RR] = 1.86, 95% CI 1.42 to 2.43). </li></ul></li><li>Unlike in men, CKS found no evidence that topical minoxidil 5% is superior to the 2% preparation and only the 2% strength is licensed for use in women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BNF 71, 2016</a>].<ul><li>Two RCTs (n = 420) found no significant difference in efficacy between a 2% concentration applied twice daily and a 5% concentration applied once or twice daily. Although one of these studies found no statistically significant difference in the number of adverse events reported in either intervention group, the number of participants reporting adverse events favoured the lower concentration in the other study. Hypertrichosis (more hair growth on areas other than the scalp), dermatitis, and itch were reported more frequently in the minoxidil 5% group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">van Zuuren et al, 2012</a>].</li></ul></li></ul><h5>Treatments not recommended</h5><ul><li>Finasteride is not licensed for use in female pattern hair loss and should not be used without specialist supervision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BNF 71, 2016</a>].<ul><li>It is contraindicated in women of childbearing age because 5-reductase inhibitors are likely to cause abnormalities (such as feminization) of the external genitalia in a male fetus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">ABPI Medicines Compendium, 2014</a>].</li></ul></li><li>Medications with anti-androgenic effects, such as spironolactone or cyproterone, are not routinely recommended without specialist advice.</li></ul><!-- end field a9a51014-e38f-4806-8f50-aaf9fd9e1be3 --><!-- end item a83a108b-9b56-4fb3-834a-e4b136dcbc85 -->","subChapters":[]}]},{"id":"2eff4998-abb2-566a-99b1-7036d3e53d7b","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field ca523730-7192-4fed-8946-da2b07b3af4e --><h3>When should I refer a woman with androgenetic alopecia?</h3><!-- end field ca523730-7192-4fed-8946-da2b07b3af4e -->","summary":null,"htmlStringContent":"<!-- begin item 8e8e0d4f-0382-466c-934f-6a09004bdf5b --><!-- begin field 0ad9f710-33b6-4dd2-ab66-37a5af4214d7 --><ul><li>Referral to a dermatologist is not usually necessary.</li><li>Consider referral to the appropriate specialist if a woman has:<ul><li>Atypical presentation or extensive hair loss — to a dermatologist with a special interest in hair, if available.</li><li>Clinical or biochemical evidence of <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/diagnosis/investigations/\">androgen excess</a> — further investigation by an endocrinologist to exclude an androgen-secreting tumour may be necessary. </li><li>Adverse psychosocial effects<em> </em><em>— </em>referral to psychological services may be necessary.</li><li>No response to available treatments in primary care — a number of specialist dermatological treatment options may be available. </li></ul></li></ul><!-- end field 0ad9f710-33b6-4dd2-ab66-37a5af4214d7 --><!-- end item 8e8e0d4f-0382-466c-934f-6a09004bdf5b -->","subChapters":[{"id":"d613fbe5-b299-5117-a183-0633822f8658","slug":"basis-for-recommendation-80e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6fe462ac-d576-4317-ab35-e52b60329178 --><h4>Basis for recommendation</h4><!-- end field 6fe462ac-d576-4317-ab35-e52b60329178 -->","summary":null,"htmlStringContent":"<!-- begin item 80ea2532-9d6c-408d-89b8-f17c17a4adb8 --><!-- begin field 656def5f-cc74-48fc-8bb9-4dd1ad1cde17 --><p>The recommendations on referral are extrapolated from European consensus guidelines on the diagnosis and management of androgenetic alopeica [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blume-Peytavi et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blumeyer et al, 2011</a>], a Cochrane systematic review of interventions for female pattern hair loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">van Zuuren et al, 2012</a>], and expert opinion in a review article on female pattern hair loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Herskovitz et al, 2013</a>].</p><h5>Secondary care management</h5><ul><li>More advanced specialist tools for assessment may be available, such as the trichogram (microscopic examination of hair roots), photographic techniques, and dermatoscopy.</li></ul><h5>Secondary care treatments</h5><ul><li>5-alpha-reductase-inhibitors — previous expert reviewers of this CKS topic noted that some specialists prescribe finasteride to women (if the woman is post-menopausal, or occasionally to pre-menopausal women who are taking effective contraception).</li><li>Anti-androgens (such as spironolactone) for women with androgen excess.</li><li>Oestrogens.</li><li>Low-level light therapy or surgery (such as hair transplantation).</li></ul><!-- end field 656def5f-cc74-48fc-8bb9-4dd1ad1cde17 --><!-- end item 80ea2532-9d6c-408d-89b8-f17c17a4adb8 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}